Literature DB >> 11448224

Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain.

J R Proudfoot1, R Betageri, M Cardozo, T A Gilmore, S Glynn, E R Hickey, S Jakes, A Kabcenell, T M Kirrane, A K Tibolla, S Lukas, U R Patel, R Sharma, M Yazdanian, N Moss, P L Beaulieu, D R Cameron, J M Ferland, J Gauthier, J Gillard, V Gorys, M Poirier, J Rancourt, D Wernic, M Llinas-Brunet.   

Abstract

p56lck is a member of the src family of tyrosine kinases and plays a critical role in the signal transduction events that lead to T cell activation. Ligands for the p56lck SH2 domain have the potential to disrupt the interaction of p56lck with its substrates and derail the signaling cascade that leads to the production of cytokines such as interleukin-2. Starting from the quintuply charged (at physiological pH) phosphorylated tetrapeptide, AcpYEEI, we recently disclosed (J. Med. Chem. 1999, 42, 722 and J. Med. Chem. 1999, 42, 1757) the design of the modified dipeptide 3, which carries just two charges at physiological pH. Here we present the elaboration of 3 to the nonpeptidic, monocharged compound, 9S. This molecule displays good binding affinity for the p56lck SH2 domain (K(d) 1 microM) and good cell permeation, and this combination of properties allowed us to demonstrate clear-cut inhibitory effects on a very early event in T cell activation, namely calcium mobilization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448224     DOI: 10.1021/jm000446q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Design and synthesis of phosphotyrosine peptidomimetic prodrugs.

Authors:  Hugo Garrido-Hernandez; Kyung D Moon; Robert L Geahlen; Richard F Borch
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

2.  NMR structure of a complex between MDM2 and a small molecule inhibitor.

Authors:  David C Fry; S Donald Emerson; Stefan Palme; Binh T Vu; Chao-Min Liu; Frank Podlaski
Journal:  J Biomol NMR       Date:  2004-10       Impact factor: 2.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.